Physician profile
John Wang
NPI 1659639607
$3,303.85
in general payments reported to CMS, 2019-2025
39 companies · $812 in 2025
The $812 reported for 2025 was more than what 82% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $473 · 2020: $153 · 2021: $364 · 2022: $396 · 2023: $557 · 2024: $549 · 2025: $812.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,918.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,918.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $826.59 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Lilly USA, LLC | $363.29 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Glaxosmithkline, LLC. | $288.84 | 2019-2025 | Shingrix, Trelegy Ellipta, Arexvy |
| Astellas Pharma US INC | $189.06 | 2019-2025 | Veozah |
| Boehringer Ingelheim Pharmaceuticals, INC. | $180.13 | 2020-2025 | Jardiance |
| Daiichi Sankyo INC. | $154.18 | 2024-2025 | Injectafer |
| Exact Sciences Corporation | $127.80 | 2024-2025 | Cologuard Collection Kit |
| Pfizer INC. | $125.13 | 2022-2025 | |
| Astrazeneca Pharmaceuticals Lp | $103.23 | 2019-2025 | Farxiga |
| Amarin Pharma, INC. | $80.65 | 2019-2021 | |
| Amgen INC. | $80.37 | 2019-2025 | Evenity |
| Dynavax Technologies Corporation | $75.83 | 2022-2023 | Heplisav-B |
| Boston Scientific Corporation | $63.72 | 2020-2025 | Captivator II |
| Bayer Healthcare Pharmaceuticals INC. | $57.65 | 2023-2025 | |
| Abbvie INC. | $57.08 | 2021-2022 |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $50.16 | 2024 | Dexcom G6 Transmitter |
| Novartis Pharmaceuticals Corporation | $32.37 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $29.77 | 2024 | Gattex |
| Alnylam Pharmaceuticals INC. | $28.84 | 2023 | Onpattro |
| Pulmonx Corporation | $28.07 | 2024 | Zephyr Delivery Catheter, Pulmonx Chartis Tablet Console, Chartis Catheter |
| Argenx US, INC. | $27.27 | 2024 | Vyvgart Hytrulo |
| Averitas Pharma INC. | $26.59 | 2023 | Qutenza |
| Verona Pharma, INC. | $25.88 | 2025 | Ohtuvayre |
| Pacira Pharmaceuticals Incorporated | $25.83 | 2025 | Exparel |
| Arbor Pharmaceuticals, INC. | $25.35 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $24.68 | 2019-2020 | |
| Biogen, INC. | $19.79 | 2025 | Leqembi |
| Ucb, INC. | $18.10 | 2024 | Nayzilam |
| Genentech USA, INC. | $17.27 | 2019 | |
| Shield Therapeutics INC | $17.15 | 2022 | |
| Collegium Pharmaceutical, INC. | $15.90 | 2025 | Jornay Pm |
| Idorsia Pharmaceuticals US INC | $15.67 | 2024 | Quviviq |
| Althera Pharmaceuticals LLC | $15.62 | 2021 | |
| Csl Behring | $15.57 | 2025 | Hizentra |
| Currax Pharmaceuticals LLC | $14.86 | 2025 | Contrave |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.63 | 2019 | |
| Gilead Sciences, INC. | $14.53 | 2019 | |
| Mannkind Corporation | $13.58 | 2019 | |
| Stryker Corporation | $12.82 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Wang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.